2-(4-Methoxyphenyl)-5,6,7,8-tetrahydro-4H-<1>benzothieno<2,3-d><1,3>oxazin-4-on | 79750-93-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(4-Methoxyphenyl)-5,6,7,8-tetrahydro-4H-<1>benzothieno<2,3-d><1,3>oxazin-4-on
• 英文别名: 2-(4-methoxyphenyl)-5,6,7,8-tetrahydro-4H-[1]benzothieno[2,3-d][1,3]oxazin-4-one；2-(4-methoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]oxazin-4-one
• CAS: 79750-93-9
• 化学式: C₁₇H₁₅NO₃S
• 分子量: 313.377
• InChiKey: WXRHELRRZLRECR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  76.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氨基-4,5,6,7-四氢苯并噻酚-3-羧酸乙酯 在 六氯乙烷 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 3.0h， 生成 2-(4-Methoxyphenyl)-5,6,7,8-tetrahydro-4H-<1>benzothieno<2,3-d><1,3>oxazin-4-on
  参考文献：
  名称：

  Achakzi, Darwizah; Ertas, Muemtaz; Appel, Rolf, Chemische Berichte, 1981, vol. 114, # 9, p. 3188 - 3194

  摘要：

  DOI：

文献信息

• ACHAKZI, D.;ERTAS, M.;APPEL, R.;WAMHOFF, H., CHEM. BER., 1981, 114, N 9, 3188-3194
  作者：ACHAKZI, D.、ERTAS, M.、APPEL, R.、WAMHOFF, H.

  DOI：——

  日期：——
• USE OF CONDENSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN DISEASES
  申请人：Arexis AB

  公开号：EP1631295B1

  公开（公告）日：2010-03-03
• Use of heterocyclic compounds as scce inhibitors
  申请人：Linschoten Marcel

  公开号：US20060258651A1

  公开（公告）日：2006-11-16

  The present invention relates to heterocyclic inhibitors of stratum corneum chymotryptic enzyme (SCCE). More particularly, the invention relates to the use of compounds with the formula (I) or (II) for treatment of certain diseases, in particular skin diseases such as pruirtus, as well as cancer such as ovarian cancer.
• US7872052B2
  申请人：——

  公开号：US7872052B2

  公开（公告）日：2011-01-18
• [EN] HETEROCYCLIC COMPOUNDS REGULATING CLOTTING<br/>[FR] COMPOSES HETEROCYCLIQUES REGULANT LA COAGULATION
  申请人：NOVO NORDISK AS

  公开号：WO2000030646A1

  公开（公告）日：2000-06-02

  The invention relates to the use of heterocyclic compounds with formulas (I) and (II), and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for treatment of coagulation-related diseases. The compounds are inhibitors of TF-FVIIa activity and thus show anticoagulant activity. The invention also relates to methods of treatment. The invention furthermore relates to novel compounds with the formula (I) or (II).